Dropout · opiate‐dependent pregnant women
Methadone showed no clear difference in dropout rate compared with buprenorphine (moderate certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR score (APGAR score ) · opiate‐dependent pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events for the mother · opiate‐dependent pregnant women
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Use of Primary Substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of primary substance compared with buprenorphine (low certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR scoreScale from: 0 to 10 · opiate‐dependent pregnant women
1 finding from 1 review
Number treated for NAS · opiate‐dependent pregnant women
Methadone showed no clear difference in number treated for NAS compared with buprenorphine (low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the child compared with buprenorphine (low certainty).
1 finding from 1 review
Unacceptability of treatment (dropouts/exclusions during the trial) · opiate‐dependent pregnant women
1 finding from 1 review
Use of substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of substance compared with oral slow‐release morphine (low certainty).
1 finding from 1 review
Completion of treatment Objective · patients with the management of opioid withdrawal
Tapered methadone showed no clear difference in completion of treatment Objective compared with any other treatment (high certainty).
1 finding from 1 review
Abstinents at · patients with the management of opioid withdrawal
Tapered methadone showed no clear difference in number of participants abstinent at compared with any other treatment (high certainty).
1 finding from 1 review
Serious adverse events or adverse events Death due to methadone use · individuals dependent on illicit opiates
1 finding from 1 review
Withdrawal symptoms · management of opium withdrawal
2 findings from 1 review
Completion of treatment · management of opium withdrawal
Pharmacological detoxification treatment may leads to higher completion of treatment: clonidine versus methadone compared with other pharmacological detoxification treatment (low certainty).
3 findings from 1 review
Completion of treatment: methadone versus methadone plus gabapentin · management of opium withdrawal
Pharmacological detoxification treatment showed no clear difference in completion of treatment: methadone versus methadone plus gabapentin compared with other pharmacological detoxification treatment (low certainty).
1 finding from 1 review
Intervention not reported
Retained in naltrexone maintenance treatment or abstinent at 12 weeks ‐ Tapered methadone comparison · patients with opioid withdrawal
The intervention showed no clear difference in retained in naltrexone maintenance treatment or abstinent at 12… (low certainty).
1 finding from 1 review